NASDAQ:NOVNNovan Stock Price, Forecast & News

Novan's stock was trading at $0.52 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NOVN shares have decreased by 4.6% and is now trading at $0.4962. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novan in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Novan.

Novan is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Novan.

Novan Inc (NASDAQ:NOVN) released its quarterly earnings results on Wednesday, May, 20th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.05. View Novan's earnings history.

2 equities research analysts have issued 1-year price targets for Novan's shares. Their forecasts range from $0.50 to $1.50. On average, they anticipate Novan's share price to reach $1.00 in the next twelve months. This suggests a possible upside of 101.5% from the stock's current price. View analysts' price targets for Novan.

News articles about NOVN stock have trended neutral this week, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Novan earned a media sentiment score of 0.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Novan.

Some companies that are related to Novan include Tyme Technologies (TYME), vTv Therapeutics (VTVT), Cerecor (CERC), Aquestive Therapeutics (AQST), Corvus Pharmaceuticals (CRVS), Evelo Biosciences (EVLO), Obseva (OBSV), Minerva Neurosciences (NERV), CELYAD SA/ADR (CYAD), KITOV PHARMA LT/S (KTOV), Mustang Bio (MBIO), InflaRx (LUMO), BIOFRONTERA AG/ADR (BFRA), Inflarx (IFRX) and Iterum Therapeutics (NRBO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novan investors own include Amplify Energy (AMPY), Amplify Energy (AMPY), Pennsylvania R.E.I.T. (PEI), Chesapeake Energy (CHK), Matinas BioPharma (MTNB), Titan Pharmaceuticals (TTNP), ADMA Biologics (ADMA), Unum Therapeutics (UMRX), Zosano Pharma (ZSAN) and Ekso Bionics (EKSO).

(NOVN) raised $46 million in an initial public offering on Wednesday, September 21st 2016. The company issued 3,800,000 shares at $11.00-$13.00 per share. Piper Jaffray acted as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Novan trades on the NASDAQ under the ticker symbol "NOVN."

Shares of NOVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NOVN stock can currently be purchased for approximately $0.50.

Novan has a market capitalization of $39.37 million and generates $4.90 million in revenue each year. The company earns $-30,640,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Novan employs 47 workers across the globe.

The official website for Novan is www.novan.com.

Novan's mailing address is 4105 HOPSON ROAD, MORRISVILLE NC, 27560. The company can be reached via phone at 919-485-8080 or via email at [email protected]